BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Inhibrx’s positive results in rare cancer prompts BLA talk
Inhibrx Biosciences Inc.’s monoclonal antibody for treating advanced or metastatic, unresectable chondrosarcoma hit its primary endpoint in a registrational phase II study,...

More in BioWorld

BioWorld MedTech

Withings provides interdisciplinary support to GLP-1 weight loss
Sustaining healthy weight loss is about so much more than cutting calories or injecting drugs, as many GLP-1 users are finding out. Withings SA continues to expand its...

More in BioWorld MedTech

BioWorld Science

At AACR-NCI-EORTC 2025, new strategies reshape the field
During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several presentations...

More in BioWorld Science

BioWorld Asia

Aimedbio’s solid tumor ADC asset goes to Boehringer in $1B deal
Antibody-drug conjugate (ADC) specialist Aimedbio Inc. announced Oct. 16 the signing of a potential $991 million deal with Boehringer Ingelheim GmbH to license out its...

More in BioWorld Asia

BioWorld Insider Podcast

Bioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment.